[{"question_number":"1","question":"A patient has normal pressure hydrocephalus (NPH) and abdominal tuberculosis. What is the most appropriate management?","options":["Thiamine","Flumazine","Copper","None of the above"],"subspecialty":"Other/Unclassified","ai_generated":true,"exam_year":"2021","exam_type":"Part Two","correct_answer":"D","correct_answer_text":"None of the above","explanation":{"option_analysis":"Normal pressure hydrocephalus requires cerebrospinal fluid diversion, most commonly via ventriculoperitoneal shunting.","pathophysiology":"In the setting of active abdominal tuberculosis, placement of a peritoneal catheter is contraindicated due to risk of infecting the shunt system.","clinical_manifestation":"Vitamins such as thiamine or copper are not indicated for hydrocephalus. Therefore, none of the listed metabolic treatments is appropriate.","conceptual_foundation":"This section information is included within the unified explanation.","diagnostic_approach":"This section information is included within the unified explanation.","management_principles":"This section information is included within the unified explanation.","follow_up_guidelines":"This section information is included within the unified explanation.","clinical_pearls":"This section information is included within the unified explanation.","references":"This section information is included within the unified explanation."},"unified_explanation":"Normal pressure hydrocephalus requires cerebrospinal fluid diversion, most commonly via ventriculoperitoneal shunting. In the setting of active abdominal tuberculosis, placement of a peritoneal catheter is contraindicated due to risk of infecting the shunt system. Vitamins such as thiamine or copper are not indicated for hydrocephalus. Therefore, none of the listed metabolic treatments is appropriate.","source_file":"part 2 2021 (2)_mcqs_processed.json","import_specialty":"Other/Unclassified","import_source":"other_unclassified_mcqs.json"},{"question_number":"10","question":"A group of doctors conducted research, and after finishing, the chairman\u2019s friend asked to add the chairman\u2019s name. He might report the names of those who refused to the chairman. What is the most appropriate action?","options":["Refuse to put the name of the chairman","Consult the Institutional Review Board (IRB)"],"subspecialty":"Other/Unclassified","ai_generated":true,"exam_year":"2021","exam_type":"Part Two","correct_answer":"B","correct_answer_text":"Consult the Institutional Review Board (IRB)","explanation":{"option_analysis":"Authorship should reflect meaningful intellectual contribution; adding the chairman\u2019s name without contribution constitutes honorary authorship and breaches ethical guidelines.","pathophysiology":"Consulting the IRB or equivalent ethics committee is the correct step to address potential coercion, protect participants\u2019 confidentiality regarding dissent, and ensure adherence to institutional and international authorship and research ethics standards.","clinical_manifestation":"Refusing outright may exacerbate conflict; seeking IRB guidance ensures due process and institutional support in resolving authorship disputes ethically.","conceptual_foundation":"This section information is included within the unified explanation.","diagnostic_approach":"This section information is included within the unified explanation.","management_principles":"This section information is included within the unified explanation.","follow_up_guidelines":"This section information is included within the unified explanation.","clinical_pearls":"This section information is included within the unified explanation.","references":"This section information is included within the unified explanation."},"unified_explanation":"Authorship should reflect meaningful intellectual contribution; adding the chairman\u2019s name without contribution constitutes honorary authorship and breaches ethical guidelines. Consulting the IRB or equivalent ethics committee is the correct step to address potential coercion, protect participants\u2019 confidentiality regarding dissent, and ensure adherence to institutional and international authorship and research ethics standards. Refusing outright may exacerbate conflict; seeking IRB guidance ensures due process and institutional support in resolving authorship disputes ethically.","source_file":"part 2 2021 (2)_mcqs_processed.json","import_specialty":"Other/Unclassified","import_source":"other_unclassified_mcqs.json"},{"question_number":"16","question":"In a scenario involving a female patient with hematologic metastasis, what is the most likely skin-related diagnosis?","options":["Skin melanoma","Basal cell carcinoma","Squamous cell carcinoma","Merkel cell carcinoma"],"subspecialty":"Other/Unclassified","ai_generated":true,"exam_year":"2021","exam_type":"Part Two","correct_answer":"A","correct_answer_text":"Skin melanoma","explanation":{"option_analysis":"Cutaneous melanoma has a high propensity for hematogenous spread, commonly to skin, subcutaneous tissue, lung, liver, and brain.","pathophysiology":"In a patient with known systemic metastasis, new cutaneous nodules or pigmented lesions are most likely metastatic melanoma.","clinical_manifestation":"Basal cell and squamous cell carcinomas are typically locally invasive and rarely metastasize hematogenously. Merkel cell carcinoma, although aggressive, is far less common than melanoma and usually presents in sun\u2010exposed areas of elderly patients. Therefore, skin melanoma is the most likely diagnosis in this context.","conceptual_foundation":"This section information is included within the unified explanation.","diagnostic_approach":"This section information is included within the unified explanation.","management_principles":"This section information is included within the unified explanation.","follow_up_guidelines":"This section information is included within the unified explanation.","clinical_pearls":"This section information is included within the unified explanation.","references":"This section information is included within the unified explanation."},"unified_explanation":"Cutaneous melanoma has a high propensity for hematogenous spread, commonly to skin, subcutaneous tissue, lung, liver, and brain. In a patient with known systemic metastasis, new cutaneous nodules or pigmented lesions are most likely metastatic melanoma. Basal cell and squamous cell carcinomas are typically locally invasive and rarely metastasize hematogenously. Merkel cell carcinoma, although aggressive, is far less common than melanoma and usually presents in sun\u2010exposed areas of elderly patients. Therefore, skin melanoma is the most likely diagnosis in this context.","source_file":"part 2 2021 (2)_mcqs_processed.json","import_specialty":"Other/Unclassified","import_source":"other_unclassified_mcqs.json"},{"correct_answer":"B","correct_answer_text":"Natalizumab.","subspecialty":"Multiple Sclerosis","explanation":"This 34-year-old woman presents with relapsing-remitting MS (RRMS): prior optic neuritis and current partial myelitis, fulfilling dissemination in time and space on MRI with both enhancing and nonenhancing lesions, and positive CSF oligoclonal bands. She also has major depression, type 1 diabetes mellitus complicated by retinopathy, neuropathy, and nephropathy, plus inflammatory bowel disease (IBD). Selecting a disease-modifying therapy (DMT) requires weighing efficacy against safety in the context of her comorbidities.  \n\nWhy Natalizumab is the Best Choice  \n\u2022 High-efficacy monoclonal antibody targeting \u03b14-integrin, blocks lymphocyte trafficking across the blood\u2013brain barrier (BBB).  \n\u2022 Indicated for patients with highly active RRMS or those with inadequate response to first-line therapies. Our patient\u2019s MRI shows multiple lesions and she has had two distinct clinical events\u2014optic neuritis and myelitis\u2014demonstrating aggressive disease.  \n\u2022 Comorbid IBD is not a contraindication; in fact, natalizumab also has efficacy in moderate to severe Crohn\u2019s disease.  \n\u2022 Does not exacerbate depression; unlike interferons, it does not carry a black-box warning for depression or suicidal ideation.  \n\u2022 No known risk of macular edema that would compound diabetic retinopathy, nor does it cause peripheral neuropathy that could worsen diabetic neuropathy.  \n\nKey Risks and Mitigation  \n\u2022 Progressive multifocal leukoencephalopathy (PML) from John Cunningham virus (JCV) reactivation. Assess baseline JCV antibody; if negative, risk is very low but requires serial monitoring every 6 months.  \n\u2022 Infusion reactions and immunogenicity \u2013 monitor for hypersensitivity during and after infusions.  \n\u2022 Regular MRI surveillance and clinical follow-up.  \n\nWhy the Other Options Are Less Appropriate  \nA. Teriflunomide  \n\u2022 Mechanism: inhibits dihydroorotate dehydrogenase, reducing pyrimidine synthesis.  \n\u2022 Side effects: hepatotoxicity, alopecia, gastrointestinal upset, and peripheral neuropathy.  \n\u2022 Our patient already has diabetic neuropathy; teriflunomide can worsen peripheral neuropathy.  \n\u2022 Teratogenic potential and prolonged elimination half-life requiring washout \u2013 problematic in women of childbearing age.  \n\nC. Fingolimod  \n\u2022 Mechanism: sphingosine-1\u2013phosphate receptor modulator, sequesters lymphocytes in lymph nodes.  \n\u2022 Side effects: bradycardia and atrioventricular conduction delays on first dose, increased risk of infections, and most importantly, macular edema.  \n\u2022 Diabetic retinopathy predisposes to macular edema; fingolimod would significantly increase this risk and worsen visual prognosis.  \n\nD. Interferon-\u03b2  \n\u2022 Mechanism: immunomodulation via cytokine signaling, reduces relapse rate by ~30%.  \n\u2022 Side effects: flu-like symptoms, injection-site reactions, elevated liver enzymes, and a well-recognized risk of depression and suicidal ideation.  \n\u2022 Our patient has a history of major depression; interferon-\u03b2 is contraindicated or used with extreme caution in patients with active depression.  \n\nKey Concepts and Pathophysiology  \n\u2022 MS is an autoimmune demyelinating disorder in which autoreactive T lymphocytes cross the BBB and attack myelin, leading to focal lesions and variable neurological deficits.  \n\u2022 DMTs are stratified by efficacy and safety: first-line injectable (interferons, glatiramer acetate) or oral moderate-efficacy (dimethyl fumarate, teriflunomide) versus high-efficacy agents (natalizumab, alemtuzumab, ocrelizumab, fingolimod).  \n\u2022 Patient-specific factors (comorbidities, childbearing plans, JCV status, MRI activity) guide DMT selection.  \n\nClinical Pearls  \n\u2022 Always assess psychiatric history before prescribing interferons.  \n\u2022 In diabetic patients, screen ophthalmologically before starting fingolimod; avoid if diabetic retinopathy is present.  \n\u2022 Teriflunomide carries a risk of peripheral neuropathy and hepatotoxicity; monitor LFTs and neurological symptoms.  \n\u2022 Natalizumab demands JCV antibody testing and vigilant PML surveillance.  \n\nReferences  \n1. Compston A, Coles A. Multiple sclerosis. Lancet. 2008;372(9648):1502\u20131517.  \n2. Polman CH, et al. A randomized, placebo-controlled trial of natalizumab for relapsing MS. N Engl J Med. 2006;354(9):899\u2013910.  \n3. Cohen JA, et al. Fingolimod versus interferon beta-1a for relapsing MS. N Engl J Med. 2010;362(5):402\u2013415.  \n4. Butler D, Ihara-Miyauchi T. Teriflunomide: a novel oral agent for MS. Expert Rev Clin Immunol. 2011;7(4):361\u2013369.  \n5. Havrdova E, et al. Safety and efficacy of natalizumab in MS. Expert Rev Neurother. 2012;12(1):89\u2013101.","question_number":"4","ai_generated":true,"exam_year":"2024","exam_type":"Promotion","options":["Teriflunoamide.","Natalizumab.","Fingolimod.","Interferon."],"question":"34 years old female with prior history of resolved right sided optic neuritis 1 year ago is currently presented with features of partial myelitis. She is known to have major depression, type 1 DM (with retinopathy, neuropathy and nephropathy) and inflammatory bowel disease. Brain and cervical magnetic resonance imaging (MRI) showed multiple enhancing and non-enhanced lesions. cerebrospinal fluid (CSF) was positive for oligoclonal bands. She is meeting the diagnosis of RRMS. What is the best management option to consider?","source_file":"promotion 2024_processed.json","import_specialty":"Multiple Sclerosis","import_source":"multiple_sclerosis_mcqs.json"},{"correct_answer":"B","correct_answer_text":"50 years old female with demyelinating lesions on brain MRI with normal spine MRI but with 6 oligoclonal bands.","subspecialty":"Multiple Sclerosis","explanation":"This patient exemplifies radiologically isolated syndrome (RIS) with magnetic resonance imaging (MRI) features typical of demyelination and cerebrospinal fluid (CSF) oligoclonal bands (OCB). Among patients with RIS, the presence of CSF oligoclonal bands is the single strongest predictor of conversion to a first clinical event fulfilling multiple sclerosis (MS) diagnostic criteria. Hence, Option B carries the highest risk of developing clinically definite MS.\n\nWhy Option B is correct\n\n1. Radiologically Isolated Syndrome (RIS) Framework: RIS refers to incidentally discovered MRI lesions suggestive of demyelination in asymptomatic individuals. The 2009 Okuda et al. RIS criteria require: abnormal brain MRI showing lesions fulfilling dissemination in space (DIS) according to the 2005 McDonald criteria, no historical accounts of clinical symptoms referable to CNS demyelination, and no better explanation for the MRI findings. In Option B, \u201cdemyelinating lesions on brain MRI\u201d suggests at least three characteristic lesions in typical locations (periventricular, juxtacortical, infratentorial), thereby fulfilling DIS.\n\n2. CSF Oligoclonal Bands: Numerous cohort studies identify positive CSF OCB as the strongest predictor of conversion from RIS to clinical MS. In the large international RIS cohort (Lebrun-Frenay et al., Lancet Neurol 2020), OCB positivity conferred a hazard ratio (HR) of ~2.2 for clinical conversion, higher than other MRI factors such as spinal cord or infratentorial lesions.\n\n3. Risk Stratification: Other predictors like age younger than 37 years, male sex, spinal cord lesions, and infratentorial lesions also increase MS risk but have lower hazard ratios (HR 1.3\u20131.7). Option B lacks spinal or infratentorial involvement but compensates with strong OCB positivity (6 bands). Even at age 50, OCB positivity outweighs the moderate risk reduction from older age.\n\n4. Clinical Implication: A patient with RIS and positive OCB should be counseled regarding higher risk of a first clinical attack and considered for close monitoring and potentially early immunotherapy in clinical trials. CSF OCB testing is a key step in the evaluation of RIS.\n\nWhy Options A, C, and D are wrong\n\nOption A: 30-year-old male with migraine, one periventricular lesion, two non-enhancing spine lesions, negative OCB\n- He has lesions in two anatomic regions (periventricular and spinal), not the required three for DIS. Without dissemination in space, he does not meet RIS criteria. Negative OCB further lowers conversion risk. Even though spinal lesions and younger age are risk factors, the overall risk is low.\n\nOption C: 31-year-old female with migraine, four small peri-callosal white matter lesions, negative OCB\n- All lesions are in the same region (pericallosal/periventricular), so DIS is not fulfilled. Negative OCB adds little predictive value. Her risk of clinically definite MS is minimal.\n\nOption D: 61-year-old male with slowly progressive cognitive decline and patchy periventricular white matter lesions\n- The clinical history of progressive cognitive decline suggests symptomatic disease, possibly vascular or neurodegenerative, not asymptomatic RIS. This does not represent RIS but rather a different pathology (e.g., small vessel ischemic disease or neurodegenerative process). Primary progressive MS requires objective clinical signs, not isolated cognitive symptoms, and MRI plaques alone without clinical correlation do not equate to RIS.\n\nKey Concepts and Pathophysiology\n\n- Demyelinating lesions in MS are perivenular, immunologically mediated attacks on CNS myelin. OCB represent intrathecal IgG synthesis, reflecting chronic B-cell activation in the CNS.\n\n- McDonald Criteria (2017 revision) define dissemination in space (\u22651 T2 lesion in \u22652 of 4 typical regions) and dissemination in time (simultaneous presence of gadolinium-enhancing and non-enhancing lesions or new T2/gadolinium-enhancing lesions on follow-up MRI).\n\n- RIS patients lack clinical symptoms but carry an average 30\u201345% risk of a first clinical event within 5\u201310 years. Predictors include OCB, spinal/infratentorial lesions, younger age, and male sex.\n\nClinical Pearls\n\n- Always perform CSF analysis (OCB) in RIS to stratify risk.\n\n- Counsel RIS patients on symptom monitoring and schedule follow-up MRI every 6\u201312 months.\n\n- Early detection of subclinical disease activity can inform discussions about disease-modifying therapies in borderline cases or clinical trials.\n\nReferences\n\n1. Okuda DT, Mowry EM, Beheshtian A, et al. Radiologically isolated syndrome: 10-year risk estimate of a clinical event. Neurology. 2020;94(8):e802\u2013e812.\n2. Lebrun-Frenay C, Mistry N, et al. The spectrum of radiologically isolated syndrome: to treat or not to treat? Lancet Neurol. 2020;19(2):134\u2013145.\n3. Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17(2):162\u2013173.\n4. Tintore M, Rovira A, R\u00edo J, et al. Brainstem lesions as a magnetic resonance imaging predictor of disability in patients with clinically isolated syndromes. Arch Neurol. 2008;65(4):499\u2013503.","question_number":"5","ai_generated":true,"exam_year":"2024","exam_type":"Promotion","options":["30 years old male with migraine and 1 small incidental periventricular white matter signal lesion with 2 non-enhancing spine MRI lesions and negative OCB.","50 years old female with demyelinating lesions on brain MRI with normal spine MRI but with 6 oligoclonal bands.","31 years old female with migraine and 4 small peri-callosal white matter signal lesion and negative OCB.","61 years old male with slowly progressive cognitive decline and MRI features of patchy periventricular white matter lesions on both hemispheres."],"question":"Regarding the radiological criteria for multiple sclerosis, which of the following statements carries the highest risk of developing clinical definite multiple sclerosis?","source_file":"promotion 2024_processed.json","import_specialty":"Multiple Sclerosis","import_source":"multiple_sclerosis_mcqs.json"}]